Junwen Huang

Dr. Junwen Huang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
XPXianru Peng
Xianru Peng
YLYuemao Li
Yuemao Li
WZWenqu Zhao
Wenqu Zhao
SYShuluan Yang
Shuluan Yang
JHJunwen Huang
Junwen Huang
HZHaijin Zhao
Haijin Zhao

13 April 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JHJunwen Huang
Junwen Huang
YCYing Chen
Ying Chen
XPXianru Peng
Xianru Peng
ZGZhaoqian Gong
Zhaoqian Gong
YWYanhong Wang
Yanhong Wang
HZHaijin Zhao
Haijin Zhao
Mitochondrial dysfunction is an essential part of the pathophysiology of asthma, and potential treatments that target the malfunctioning mitochondria have attracted widespread attention. We have previously demonstrated that aberrant epithelial β-catenin signaling played a crucial role in a toluene diisocyanate (TDI)-induced steroid-insensitive asthma model. The objective of this study was to determine if the mitochondrially targeted antioxidant mitoquinone(MitoQ) regulated the activation of β-catenin in TDI-induced asthma. Mice were sensitized and challenged with TDI to generate a steroid-insensitive asthma model. Human bronchial epithelial cells (16HBE) were exposed to TDI-human serum albumin (HSA) and ethidium bromide(EB) to simulate the TDI-induced asthma model and mitochondrial dysfunction. MitoQ dramatically attenuated TDI-induced AHR, airway inflammation, airway goblet cell metaplasia, and collagen deposition and markedly protected epithelial mitochondrial functions by preserving mass and diminishing the production of reactive oxygen species (ROS). MitoQ administration stabilized β-catenin destruction complex from disintegration and inhibited the activation of β-catenin. Similarly, YAP1, an important constituent of β-catenin destruction complex, was inhibited by Dasatinib, which alleviated airway inflammation and the activation of β-catenin, and restored mitochondrial mass. In vitro, treating 16HBE cells with EB led to the activation of YAP1 and β-catenin signaling, decreased the expression of glucocorticoid receptors and up-regulated interleukin (IL)-1β, IL6 and IL-8 expression. Our results indicated that mitochondria mediates airway inflammation by regulating the stability of the β-catenin destruction complex and MitoQ might be a promising therapeutic approach to improve airway inflammation and severe asthma. The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions.

1 January 2024 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
DHDapeng Hu
Dapeng Hu
JHJunwen Huang
Junwen Huang
WZWenqu Zhao
Wenqu Zhao
MXMaosheng Xu
Maosheng Xu
YMYanyan Ma
Yanyan Ma
HZHaijin Zhao
Haijin Zhao
Purpose: Identifying prognosis for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is challenging. Eosinophils and platelet are involved in the development of COPD, which may predict adverse events. The objective of this study was to determine the effect of the eosinophil to platelet ratio (EPR) in predicting adverse events in patients with AECOPD who visited the emergency department. Patients and Methods: The records of patients with AECOPD treated at Dalian Municipal Friendship Hospital from January 2018 to December 2020 were retrospectively reviewed. The relationship between the clinical characteristics and EPR, as cut-off value of 0.755, was evaluated. Results: A total of 508 patients with an AECOPD (316 male, 192 female) were included. An optimal AUC cutoff of 0.755 for the EPR segregated the patients into 2 groups with significantly different mortality (25.3% vs 5.5%, P < 0.001). The same mortality risk with lower EPR was observed among the patients with emergency room attendance (35.6% vs 11.1%, P < 0.001). A model including EPR < 0.755, exacerbation history, PaO2 < 60mmHg, PaCO2 > 50 mm Hg, hypoalbuminemia and age ≥ 80 was developed to predict death risk and showed good performance. Conclusion: During severe COPD exacerbation, an EPR < 0.755 preceding therapy can predict worse outcomes in patients with an AECOPD.

27 June 2026 in Redox Biology
Verified
Journal Article
Open access
YCYing Chen
Ying Chen
JHJunwen Huang
Junwen Huang
ZGZhaoqian Gong
Zhaoqian Gong
YLYuemao Li
Yuemao Li
YCYaoxin Chen
Yaoxin Chen
HZHaijin Zhao
Haijin Zhao
Metabolic dysregulation is increasingly recognized as a critical contributor to asthma pathogenesis. Emerging clinical and metabolomic evidence has implicated histidine metabolism in asthma; however, whether histidine metabolic reprogramming contributes to severe asthma pathogenesis and the underlying mechanisms remain unclear. Here, we integrated clinical cohort analyses, multi-omics profiling, primary human airway epithelial cell experiments, and both toluene diisocyanate (TDI)- and house dust mite/lipopolysaccharide (HDM/LPS)-induced severe asthma murine models to systematically delineate this relationship. Histidine levels were markedly elevated in induced sputum from asthma patients and were strongly associated with disease severity, airflow limitation, and inflammatory indices. Integrated metabolomic and transcriptomic analyses revealed a pathogenic reprogramming of histidine metabolism, characterized by enhanced histamine biosynthesis and depletion of the cytoprotective carnosine, thereby amplifying airway inflammatory responses. Pharmacological blockade of histidine metabolism significantly alleviated airway hyperresponsiveness, inflammation, and structural remodeling in both TDI- and HDM/LPS-induced severe asthma models. Mechanistically, histidine metabolic dysregulation drives oxidative stress mediated mitochondrial dysfunction, leading to mtDNA release and subsequent activation of mt-ND6/FPR2 signaling, ultimately triggering necroptotic epithelial cell death. Collectively, these findings define a histidine-driven oxidative stress-mtDNA-necroptosis axis as a central mechanism of airway inflammation in severe asthma, offering new therapeutic opportunities through metabolic targeting.

8 April 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
JHJunwen Huang
Junwen Huang
WZWenqu Zhao
Wenqu Zhao
YCYing Chen
Ying Chen
YCYaoxin Chen
Yaoxin Chen
ZGZhaoqian Gong
Zhaoqian Gong
HZHaijin Zhao
Haijin Zhao
Mitochondrial dysfunction drives persistent inflammation in severe asthma, yet its upstream metabolic regulation remains unclear. Induced sputum from patients with severe asthma was analyzed and integrated with transcriptomic datasets from independent cohorts. Two mouse models (C57BL/6J) were used for in vivo validation with multi-omics profiling, and mechanistic studies were performed in air–liquid interface-cultured primary human airway epithelial cells. Glutathione reduced form (GSHr) was markedly depleted in sputum and associated with poor disease control and mixed granulocytic inflammation in patients with severe asthma. Multi-omics analyses revealed coordinated disruption of glutathione (GSH) metabolism, including oxidized GSH accumulation, reduced synthesis and glutathione-S-transferase activity, and impaired mitochondrial GSH transport. GSH supplementation alleviated airway inflammation, oxidative stress, and mitochondrial dysfunction, whereas pharmacological inhibition of GST exacerbated these effects. Mitochondrial analyses identified suppressed SLC25A39 expression as a key mediator of defective GSH transport and redox imbalance. Transcriptomic profiling of airway biopsies showed upregulation of Neuropilin-1 (Nrp1), closely associated with altered glutathione pathways. Targeting the Nrp1 b1 domain restored mitochondrial GSH metabolism and attenuated airway inflammation. These findings identify an Nrp-centered metabolic pathway that disrupts mitochondrial homeostasis and drives inflammatory amplification, highlighting mitochondria-targeted therapeutic strategies for severe asthma.